< Zurück zu den aktuellen Neuigkeiten & Events

UPC

Unitary Patent Renewal Fees – proposed figures revealed

März 2015

Ever since the prospect of a Unitary Patent for Europe became a reality, the subject of cost has been hotly debated. Will a Unitary Patent save me money? But with so many unknowns, the question has been like a puzzle.

According to various sources, we could have the first piece in the puzzle, with the EPO having made a proposal on the level of renewal fees. In a document „Proposals for the level of renewal fees for European patents with unitary effect“, (which we’ve yet to see a copy of) submitted by the President of the EPO to the Select Committee of the Administrative Council for their opinion, the EPO has come up with the following proposal:

To meet the requirements set out in Article 12 of the Regulation on the Unitary Patent, the EPO has allegedly proposed the following structure for setting unitary patent renewal fees:

  • years 3 to 5: the level of the EPO’s internal renewal fees (IRF) [these are the fees payable to the EPO for pending patent applications currently]
  • years 6 to 9: a transitional level between the IRF level and the year 10 level
  • from year 10, a level equivalent to the total sum of the national renewal fees payable in the states in
    which European patents are most frequently validated (TOP level)

Furthermore, based on this, two specific proposals are made – one where the Year 10 onwards level is based on current renewal fee levels for FOUR European countries (TOP 4 level) and one where the Year 10 onwards level is based on current renewal fee levels for FIVE European countries (TOP 5 level) but with a reduction for certain categories of patentees, namely SMEs, natural persons, non-profit organisations, universities and public research
organisations.

Based on these proposals, the cost of obtaining a UP would be more expensive than current filing strategies, if for example patentees usually validate in 3 or less states. And of course, given that it will not be possible to be selective as to EP countries which are maintained throughout the life of the patent, there is no option to scale down costs towards the end of the patent term.

We still need more pieces in the puzzle to get the full picture on whether a UP will save money in the long run.

Aktuelle Neuigkeiten

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Weiterlesen

PRESSEMITTEILUNG HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland

HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland HGF freut sich, die Aufnahme von drei neuen Partnern bekannt zu geben, die die Präsenz des …

Weiterlesen

Quinas Technology Wins WIPO Global Award for Innovation in ICT

Our client, Quinas Technology, has been named the winner of the WIPO Global Award 2025 in the ICT Startup category. Quinas is a spin-out from Lancaster University. We have worked …

Weiterlesen

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Weiterlesen

Briefing Note: UKIPO SEP Consultation

Overview and Strategic Context The UKIPO’s 2025 consultation on Standard Essential Patents (SEPs), announced on 15 July 2025, signals a potential policy shift in how the UK approaches SEP licensing …

Weiterlesen

HGF recognised in Managing IP’s New “Trusted Talent” Table in Germany

We are proud to announce that HGF has been ranked in Managing IP’s newly launched Trusted Talent table in Germany, a recognition of our ongoing commitment to excellence in intellectual …

Weiterlesen

ICELAND left out in the cold by the General Court

Earlier in the month, the EU General Court issued its decision on Iceland Foods Ltd’s appeal of a decision of the Grand Board of Appeal of EUIPO to invalidate an …

Weiterlesen

A leading case - beware sequence errors in patent claims

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Mr Justice Meade – 20 May 2025 The UK Patents Court has held that Samsung Bioepis’ and Amgen’s …

Weiterlesen